


AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method for manufacturing hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester (clopidogrel hydrogen sulphate) of formula I



(I)

in crystalline Form I, said method comprising separating crystalline Form I of characterized ~~in that~~ the compound of formula I ~~is separated~~ out of a solution of clopidogrel in the form of the free base or salt in a solvent selected from the group consisting series of primary, secondary and tertiary C1-C5 alcohols ~~or their~~, esters of primary, secondary and tertiary C1-C5 alcohols with C1-C4 carboxylic acids, and ~~or optionally~~ of mixtures thereof.

Claim 2 (Currently Amended): The method according to claim 1, wherein crystalline Form I of characterized ~~in that~~ the compound of formula I is crystallized ~~crystallised~~ out of a solution of clopidogrel hydrogen sulphate by cooling the solution ~~down~~.

Claim 3 (Currently Amended): The method according to claim 1, wherein crystalline Form I of characterized ~~in that~~ the compound of formula I is precipitated out of a solution of the clopidogrel base or ~~of its~~ salt by adding ~~of~~ 0.6 to 1.1 equivalent of sulphuric acid to the solution.

Claim 4 (Currently Amended): The method according to claim 3, wherein crystalline Form I of characterized ~~in that~~ the compound of formula I is precipitated out of a solution of

clopidogrel in the form of the free base or salt in a solvent selected from the group consisting of primary, secondary and tertiary C1 to C5 alcohols.

Claim 5 (Currently Amended): The method according to claim 4, wherein the crystalline Form I of the compound of formula I is precipitated ~~characterized in that the precipitation is performed~~ out of a solution of clopidogrel in the form of the free base or salt in 2-propanol.

Claim 6 (Currently Amended): The method according to claim 5, wherein the crystalline Form I is precipitated out of a solution of clopidogrel in the form of the free base or salt in 2-propanol ~~characterized in that the precipitation is performed~~ at a temperature between -5 and 15 °C after ~~and~~ the solution is inoculated with crystals of Form I.

Claim 7 (Cancelled)

Claim 8 (New): The method according to claim 1, wherein crystalline Form I of the compound of formula I is precipitated out of a solution of clopidogrel base or salt by adding 1.1 to 1.5 equivalent of sulphuric acid to the solution.

Claim 9 (New): The method according to claim 8, wherein crystalline Form I of the compound of formula I is precipitated out of a solution of clopidogrel in the form of the free base or salt in a solvent selected from the group consisting of esters of primary, secondary and tertiary C1-C5 alcohols with C1-C4 carboxylic acids.

Claim 10 (New): The method according to claim 9, wherein crystalline Form I of the compound of formula I is precipitated out of a solution of clopidogrel in the form of the free base or salt in n-butyl acetate.

Claim 11 (New): The method according to claim 1, wherein the crystalline Form I of the compound of formula I is precipitated out of a solution of clopidogrel hydrogen sulphate in n-butyl acetate.

Claim 12 (New): The method according to claim 1, wherein crystalline Form I of the compound of formula I is precipitated out of a solution of clopidogrel base in a solvent selected from the group consisting of 2-propanol, n-butyl acetate, and mixtures thereof, by adding concentrated sulphuric acid to the solution.